FDA grants rare pediatric disease designation for BioMarin’s drisapersen to treat DMD
Earlier, drisapersen has also secured orphan and fast track status, breakthrough therapy designation, as well as priority review status from the FDA. According to FDA, a rare pediatric
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.